210 related articles for article (PubMed ID: 36341700)
1. Pentoxifylline as an adjunctive in treatment of negative symptoms in chronic schizophrenia: A double-blind, randomized, placebo-controlled trial.
Abdallah MS; Mosalam EM; Hassan A; Ramadan AN; Omara-Reda H; Zidan AA; Samman WA; El-Berri EI
CNS Neurosci Ther; 2023 Jan; 29(1):354-364. PubMed ID: 36341700
[TBL] [Abstract][Full Text] [Related]
2. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
Hosseini SM; Farokhnia M; Rezaei F; Gougol A; Yekehtaz H; Iranpour N; Salehi B; Tabrizi M; Tajdini M; Ghaleiha A; Akhondzadeh S
Eur Neuropsychopharmacol; 2014 Jun; 24(6):846-55. PubMed ID: 24636461
[TBL] [Abstract][Full Text] [Related]
3. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.
Modabbernia A; Rezaei F; Salehi B; Jafarinia M; Ashrafi M; Tabrizi M; Hosseini SM; Tajdini M; Ghaleiha A; Akhondzadeh S
CNS Drugs; 2013 Jan; 27(1):57-65. PubMed ID: 23233269
[TBL] [Abstract][Full Text] [Related]
4. Cilostazol adjunctive therapy in treatment of negative symptoms in chronic schizophrenia: Randomized, double-blind, placebo-controlled study.
Rezaei F; Mesgarpour B; Jeddian A; Zeionoddini A; Mohammadinejad P; Salardini E; Shahriari M; Zeinoddini A; Akhondzadeh S
Hum Psychopharmacol; 2017 Jul; 32(4):. PubMed ID: 28421639
[TBL] [Abstract][Full Text] [Related]
5. A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia.
Farokhnia M; Sabzabadi M; Pourmahmoud H; Khodaie-Ardakani MR; Hosseini SM; Yekehtaz H; Tabrizi M; Rezaei F; Salehi B; Akhondzadeh S
Psychopharmacology (Berl); 2014 Feb; 231(3):533-42. PubMed ID: 24013610
[TBL] [Abstract][Full Text] [Related]
6. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Lane HY; Chang YC; Liu YC; Chiu CC; Tsai GE
Arch Gen Psychiatry; 2005 Nov; 62(11):1196-204. PubMed ID: 16275807
[TBL] [Abstract][Full Text] [Related]
7. L-lysine as an adjunct to risperidone in patients with chronic schizophrenia: a double-blind, placebo-controlled, randomized trial.
Zeinoddini A; Ahadi M; Farokhnia M; Rezaei F; Tabrizi M; Akhondzadeh S
J Psychiatr Res; 2014 Dec; 59():125-31. PubMed ID: 25227564
[TBL] [Abstract][Full Text] [Related]
8. The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial.
Iranpour N; Zandifar A; Farokhnia M; Goguol A; Yekehtaz H; Khodaie-Ardakani MR; Salehi B; Esalatmanesh S; Zeionoddini A; Mohammadinejad P; Zeinoddini A; Akhondzadeh S
Hum Psychopharmacol; 2016 Mar; 31(2):103-12. PubMed ID: 26856695
[TBL] [Abstract][Full Text] [Related]
9. Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia.
Usall J; López-Carrilero R; Iniesta R; Roca M; Caballero M; Rodriguez-Jimenez R; Oliveira C; Bernardo M; Corripio I; Sindreu SD; González Piqueras JC; Felipe AE; Fernandez de Corres B; Ibáñez A; Huerta R;
J Clin Psychiatry; 2014 Jun; 75(6):608-15. PubMed ID: 25004184
[TBL] [Abstract][Full Text] [Related]
10. Citicoline (CDP-choline) add-on therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial.
Ghajar A; Gholamian F; Tabatabei-Motlagh M; Afarideh M; Rezaei F; Ghazizadeh-Hashemi M; Akhondzadeh S
Hum Psychopharmacol; 2018 Jul; 33(4):e2662. PubMed ID: 29901250
[TBL] [Abstract][Full Text] [Related]
11. Risperidone combination therapy with adalimumab for treatment of chronic schizophrenia: a randomized, double-blind, placebo-controlled clinical trial.
Motamed M; Karimi H; Sanjari Moghaddam H; Taherzadeh Boroujeni S; Sanatian Z; Hasanzadeh A; Khodaei Ardakani MR; Akhondzadeh S
Int Clin Psychopharmacol; 2022 May; 37(3):92-101. PubMed ID: 35258035
[TBL] [Abstract][Full Text] [Related]
12. Minocycline adjunctive treatment to risperidone for negative symptoms in schizophrenia: Association with pro-inflammatory cytokine levels.
Zhang L; Zheng H; Wu R; Zhu F; Kosten TR; Zhang XY; Zhao J
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jul; 85():69-76. PubMed ID: 29678772
[TBL] [Abstract][Full Text] [Related]
13. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
Kane JM; Correll CU; Goff DC; Kirkpatrick B; Marder SR; Vester-Blokland E; Sun W; Carson WH; Pikalov A; Assunção-Talbott S
J Clin Psychiatry; 2009 Oct; 70(10):1348-57. PubMed ID: 19906340
[TBL] [Abstract][Full Text] [Related]
14. Vortioxetine as adjunctive therapy to risperidone for treatment of patients with chronic schizophrenia: A randomised, double-blind, placebo-controlled clinical trial.
Moazen-Zadeh E; Bayanati S; Ziafat K; Rezaei F; Mesgarpour B; Akhondzadeh S
J Psychopharmacol; 2020 May; 34(5):506-513. PubMed ID: 32122230
[TBL] [Abstract][Full Text] [Related]
15. Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial.
Akhondzadeh S; Ghayyoumi R; Rezaei F; Salehi B; Modabbernia AH; Maroufi A; Esfandiari GR; Naderi M; Ghebleh F; Tabrizi M; Rezazadeh SA
Psychopharmacology (Berl); 2011 Feb; 213(4):809-15. PubMed ID: 20949350
[TBL] [Abstract][Full Text] [Related]
16. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety.
Anil Yağcioğlu AE; Kivircik Akdede BB; Turgut TI; Tümüklü M; Yazici MK; Alptekin K; Ertuğrul A; Jayathilake K; Göğüş A; Tunca Z; Meltzer HY
J Clin Psychiatry; 2005 Jan; 66(1):63-72. PubMed ID: 15669890
[TBL] [Abstract][Full Text] [Related]
17. Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo controlled trial.
Kianimehr G; Fatehi F; Hashempoor S; Khodaei-Ardakani MR; Rezaei F; Nazari A; Kashani L; Akhondzadeh S
Daru; 2014 Jul; 22(1):55. PubMed ID: 25012765
[TBL] [Abstract][Full Text] [Related]
18. L-Theanine adjunct to risperidone in the treatment of chronic schizophrenia inpatients: a randomized, double-blind, placebo-controlled clinical trial.
Shamabadi A; Fattollahzadeh-Noor S; Fallahpour B; A Basti F; Khodaei Ardakani MR; Akhondzadeh S
Psychopharmacology (Berl); 2023 Dec; 240(12):2631-2640. PubMed ID: 37697164
[TBL] [Abstract][Full Text] [Related]
19. Duloxetine Add-On to Risperidone for Treatment of Negative Symptoms in Patients with Stable Schizophrenia: Randomized Double-Blind Placebo-Controlled Study.
Nikbakhat MR; Arabzadeh S; Zeinoddini A; Khalili Z; Rezaei F; Mohammadinejad P; Ghaleiha A; Akhondzadeh S
Pharmacopsychiatry; 2016 Jul; 49(4):162-9. PubMed ID: 26902281
[TBL] [Abstract][Full Text] [Related]
20. A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia.
Salimi S; Fotouhi A; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Mohammadi MR; Noorbala AA; Ahmadi-Abhari SA; Hajiazim M; Abbasi SH; Akhondzadeh S
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):726-32. PubMed ID: 18096287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
